Literature DB >> 3643886

Extracellular release of antimicrobial defensins by human polymorphonuclear leukocytes.

T Ganz.   

Abstract

Human polymorphonuclear leukocytes (PMN) contain three antimicrobial and cytotoxic peptides which belong to a family of mammalian granulocyte peptides named defensins. To determine their potential availability for extracellular microbicidal or cytotoxic events, we quantified the extracellular release of defensins after stimulation of human PMN with phorbol myristate acetate and opsonized zymosan. As determined by enzyme immunoassay and confirmed by polyacrylamide gel electrophoresis and densitometry, 10(6) human PMN contained 4 to 5 micrograms of defensins. After stimulation with a high concentration of phorbol myristate acetate (1 microgram/ml), about 8% of PMN defensins were found in the media. Release of defensins correlated best with the release of azurophil granule marker beta-glucuronidase or elastase and poorly with the release of either the specific granule marker lactoferrin or cytoplasmic lactate dehydrogenase. Phagocytosis of opsonized zymosan resulted in the extracellular release of less than 3% of PMN defensins. The factors responsible for less release of defensins into media relative to the release of other azurophil granule proteins may include heterogeneity of azurophil granules and the affinity of defensins for cellular surfaces and opsonized particles. In vivo, defensins are most likely to reach effective microbicidal or cytotoxic concentrations in PMN-rich exudates (pus), in confined environments of the phagolysosomes, or in intercellular clefts between PMN and their targets.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3643886      PMCID: PMC260375          DOI: 10.1128/iai.55.3.568-571.1987

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  17 in total

1.  In vitro tumor cell cytolysis mediated by peptide defensins of human and rabbit granulocytes.

Authors:  A Lichtenstein; T Ganz; M E Selsted; R I Lehrer
Journal:  Blood       Date:  1986-12       Impact factor: 22.113

2.  The synthesis and analytical use of a highly sensitive and convenient substrate of elastase.

Authors:  J Bieth; B Spiess; C G Wermuth
Journal:  Biochem Med       Date:  1974-12

3.  The immunologic release of constituents from neutrophil leukocytes. II. Mechanisms of release during phagocytosis, and adherence to nonphagocytosable surfaces.

Authors:  P M Henson
Journal:  J Immunol       Date:  1971-12       Impact factor: 5.422

4.  Computer analysis of radioligand assay and radioimmunoassay data.

Authors:  D Rodbard; J E Lewald
Journal:  Acta Endocrinol Suppl (Copenh)       Date:  1970

Review 5.  Antimicrobial activity of phagocyte granule proteins.

Authors:  T Ganz; M E Selsted; R I Lehrer
Journal:  Semin Respir Infect       Date:  1986-06

6.  Primary structures of three human neutrophil defensins.

Authors:  M E Selsted; S S Harwig; T Ganz; J W Schilling; R I Lehrer
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

7.  Newborn rabbit alveolar macrophages are deficient in two microbicidal cationic peptides, MCP-1 and MCP-2.

Authors:  T Ganz; M P Sherman; M E Selsted; R I Lehrer
Journal:  Am Rev Respir Dis       Date:  1985-10

8.  Intracellular and extracellular degranulation of human polymorphonuclear azurophil and specific granules induced by immune complexes.

Authors:  M S Leffell; J K Spitznagel
Journal:  Infect Immun       Date:  1974-12       Impact factor: 3.441

9.  Correlation of binding of rabbit granulocyte peptides to Candida albicans with candidacidal activity.

Authors:  R I Lehrer; D Szklarek; T Ganz; M E Selsted
Journal:  Infect Immun       Date:  1985-07       Impact factor: 3.441

10.  Defensins. Natural peptide antibiotics of human neutrophils.

Authors:  T Ganz; M E Selsted; D Szklarek; S S Harwig; K Daher; D F Bainton; R I Lehrer
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

View more
  59 in total

1.  Defensins impair phagocytic killing by neutrophils in biomaterial-related infection.

Authors:  S S Kaplan; R P Heine; R L Simmons
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

2.  Dynamic changes in neutrophil defensins during endotoxemia.

Authors:  M E Klut; B A Whalen; J C Hogg
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

3.  Trypsin and host defence: a new role for an old enzyme.

Authors:  M Bajaj-Elliott
Journal:  Gut       Date:  2003-02       Impact factor: 23.059

Review 4.  Defensins: microbicidal and cytotoxic peptides of mammalian host defense cells.

Authors:  T Ganz; A Oren; R I Lehrer
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

Review 5.  Defensins: ancient but potentially dangerous weapons in the armoury.

Authors:  D Burnett
Journal:  Thorax       Date:  1992-03       Impact factor: 9.139

Review 6.  Antibiotic proteins of human neutrophils.

Authors:  J K Spitznagel
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

7.  Biomaterials selectively modulate interactions between human blood-derived polymorphonuclear leukocytes and monocytes.

Authors:  Hannah C Cohen; Evan J Joyce; W John Kao
Journal:  Am J Pathol       Date:  2013-06       Impact factor: 4.307

Review 8.  Host defense peptides in wound healing.

Authors:  Lars Steinstraesser; Till Koehler; Frank Jacobsen; Adrien Daigeler; Ole Goertz; Stefan Langer; Marco Kesting; Hans Steinau; Elof Eriksson; Tobias Hirsch
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354

9.  Inhibition of intracellular Histoplasma capsulatum replication by murine macrophages that produce human defensin.

Authors:  M A Couto; L Liu; R I Lehrer; T Ganz
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

10.  In vitro activity of the antimicrobial peptides human and rabbit defensins and porcine leukocyte protegrin against Mycobacterium tuberculosis.

Authors:  Y Miyakawa; P Ratnakar; A G Rao; M L Costello; O Mathieu-Costello; R I Lehrer; A Catanzaro
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.